RAM 1X2GB 2GB Memory A38 110-3120ss 110-3119la, 110-3110Nr, 110-3110ez Mini HP 4 Memory (RAM)


  1. Home
  2. RAM 1X2GB 2GB Memory A38 110-3120ss 110-3119la, 110-3110Nr, 110-3110ez Mini HP 4
  1. facebook
  2. twitter
  3. linkedin
  4. pinterest
2GB 1X2GB RAM Memory 4 HP Mini 110-3110ez 110-3110Nr, 110-3119la, 110-3120ss A38
Condition: New: A brand-new, unused, unopened, undamaged item in its original packaging (where packaging is Number of Pins: 200
Brand:

Computer Memory Solutions

Capacity per Module: 2GB
Type: DDR2 SDRAM Number of Modules: 1
Country/Region of Manufacture: United States Total Capacity: 2GB
MPN:

QG978EA, QG972EA,

Bus Speed: PC2-5300 (DDR2-667)
Form Factor: SO-DIMM UPC:

Does not apply




published on tue nov 09 2021

RAM 1X2GB 2GB Memory A38 110-3120ss 110-3119la, 110-3110Nr, 110-3110ez Mini HP 4 Memory (RAM)

gandhi, s., klein, j., robertson, a., pena-hernandez, m. a.,

RAM 1X2GB 2GB Memory A38 110-3120ss 110-3119la, 110-3110Nr, 110-3110ez Mini HP 4 Memory (RAM)

lin, m. j., roychoudhury, p., lu, p., fournier, j., ferguson, d., mohamed bakhash, s. a., muenker, m. c., srivathsan, a., wunder, e. a., kerantzas, n., wang, w., pyle, a., wilen, c. b., ogbuagu, o., greninger ,, a. l., iwasaki, a., schulz, w. l., ko, a. i.

sars-cov-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. we present a case of an immunocompromised patient with acquired b-cell deficiency who developed an indolent, protracted course of sars-cov-2 infection. remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. whole genome sequencing identified a mutation, e802d, in the nsp12 rna-dependent rna polymerase which was not present in pre-treatment specimens. in vitro experiments demonstrated that the mutation conferred a ~6-fold increase in remdesivir ic50 but resulted in a fitness cost in the absence of remdesivir. sustained clinical and virologic response was achieved after treatment with casirivimab-imdevimab. although the fitness cost observed in vitro may limit the risk posed by e802d,

, this case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with sars-cov-2 infection.

509
1.2k
EVGENIA.RU RSS